XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Balance Sheet Components
 9 Months Ended
Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components Balance Sheet Components
Prepaid Expense and Other Current Assets
Prepaid expense and other current assets consisted of the following:
December 31, 2023March 31, 2023
(in thousands)
Prepaid expenses$11,454 $13,244 
Other receivables5,867 3,003 
Other current assets2,779 2,977 
Prepaid expenses and other current assets$20,100 $19,224 
Property and Equipment, Net
Property and equipment, net consisted of the following:
December 31, 2023March 31, 2023
(in thousands)
Computer and software$9,580 $10,376 
Laboratory equipment and software52,803 52,785 
Furniture and office equipment8,963 8,946 
Leasehold improvements41,061 40,964 
Capitalized asset retirement obligations853 853 
Property and equipment, gross113,260 113,924 
Less: accumulated depreciation and amortization(82,990)(75,316)
Property and equipment, net$30,270 $38,608 
Depreciation and amortization expense was $2.9 million and $3.7 million for the three months ended December 31, 2023 and 2022, respectively, and $8.9 million and $11.5 million for the nine months ended December 31, 2023 and 2022, respectively. There were no impairments to property and equipment for the three and nine months ended December 31, 2023, and an immaterial impairment to property and equipment for the three and nine months ended December 31, 2022.
Internal-Use Software, Net
Internal-use software, net consisted of the following:
December 31, 2023March 31, 2023
(in thousands)
Capitalized internal-use software$33,349 $25,180 
Less: accumulated amortization(13,522)(9,519)
Internal-use software, net$19,827 $15,661 
The Company capitalized $2.7 million and $3.5 million in internal-use software during the three months ended December 31, 2023 and 2022, respectively, and $9.6 million and $7.8 million in internal-use software during the nine months ended December 31, 2023 and 2022, respectively. In addition, the Company wrote off $1.1 million of internal-use software in the three months ended September 30, 2023 related to the disposition of Lemonaid Health Limited; refer to Note 17, “Disposition of Subsidiary” for additional information. During the three and nine months ended December 31, 2023, the Company wrote off an immaterial impairment charge related to internal-use software that will not be utilized in the future. Impairment to internal-use software was nil and $0.5 million during the three and nine months ended December 31, 2022, respectively.
Amortization and impairment of internal-use software was $1.9 million and $1.1 million for the three months ended December 31, 2023 and 2022, respectively, and $4.4 million and $3.6 million for the nine months ended December 31, 2023 and 2022, respectively.
Intangible Assets, Net
Intangible assets, net consisted of the following:
December 31, 2023
Weighted Average Remaining Useful Life
(Years)
Gross Carrying Amount
Accumulated Amortization
Net Carrying Amount
(in thousands, except years)
Customer relationships0.0$14,900 $(14,900)$— 
Partnerships7.89,000 (1,950)7,050 
Trademark2.811,000 (4,767)6,233 
Developed technology4.824,100 (7,460)16,640 
Non-compete agreements2.82,800 (1,213)1,587 
Patents4.85,500 (1,776)3,724 
Total intangible assets$67,300 $(32,066)$35,234 
 March 31, 2023
Weighted Average Remaining Useful Life
(Years)
Gross Carrying Amount
Accumulated Amortization
Cumulative Impairment Charge
Cumulative Currency Translation
Net Carrying Amount
(in thousands, except years)
Customer relationships0.6$14,900 $(10,554)$— $— $4,346 
Partnerships8.623,200 (4,385)(9,968)(1,122)7,725 
Trademark3.611,000 (3,117)— — 7,883 
Developed technology5.624,100 (4,877)— — 19,223 
Non-compete agreements3.62,800 (793)— — 2,007 
Patents5.55,500 (1,164)— — 4,336 
Total intangible assets$81,500 $(24,890)$(9,968)$(1,122)$45,520 
Amortization expense for intangible assets was $2.6 million and $4.5 million for the three months ended December 31, 2023 and 2022, respectively, and $10.3 million and $13.4 million for the nine months ended December 31, 2023 and 2022, respectively.
During the third quarter of fiscal 2023, due to decreased revenue associated with a delayed product launch and margin forecasts for the U.K. partnership business, the Company performed an interim quantitative impairment test for the U.K. partnership asset group as of December 31, 2022. The fair value of the asset group was calculated using a discounted cash flow and was determined to be lower than its carrying value. As a result, the Company recorded a $10.0 million impairment charge to write down the value of the partnership intangible asset to its estimated fair value. The charge was recorded within sales and marketing expenses in its Consumer and Research Services segment in the condensed consolidated statements of operations and comprehensive loss during the third quarter of fiscal 2023. There was no impairment to intangible assets during the three and nine months ended December 31, 2023.
Estimated future amortization expense of the identified intangible assets as of December 31, 2023 was as follows:
 Estimated Amortization
 (in thousands)
Fiscal years ending March 31, 
Remainder of 2024 (Remaining three months)$1,980 
20257,919 
20267,919 
20276,769 
20285,006 
Thereafter5,641 
Total estimated future amortization expense$35,234 
Goodwill
The following table presents the changes in the carrying amount of goodwill for the Consumer and Research Services reporting unit.
Amount
(in thousands)
As of March 31, 2023$351,744 
Less: Impairment
(198,800)
As of December 31, 2023$152,944 
As a result of a sustained decline in market capitalization, based on the Company’s publicly quoted share price, lower than expected financial performance and macroeconomic conditions that existed during the three months ended December 31, 2023, the Company performed an impairment assessment of goodwill acquired as part of the Lemonaid Health acquisition. The Company utilized the income approach (discounted cash flow method) corroborated by the market approach (guideline public company method), which are Level 3 non-recurring fair value measurements. The Company recognized a non-cash, pre-tax goodwill impairment charge of $198.8 million during the three and nine months ended December 31, 2023, which was included in goodwill impairment in the unaudited condensed consolidated statements of operations and comprehensive loss in the Consumer and Research Services segment. There was no impairment to goodwill for the three and nine months ended December 31, 2022.

Accrued Expense and Other Current Liabilities
Accrued expense and other current liabilities consisted of the following:
December 31, 2023March 31, 2023
(in thousands)
Accrued payables$13,090 $17,030 
Accrued compensation and benefits4,601 5,898 
Accrued vacation7,310 8,839 
Accrued bonus5,740 21,600 
Accrued clinical expenses10,172 11,707 
Accrued taxes and other1,211 1,356 
Total accrued expenses and other current liabilities$42,124 $66,430